Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Travere is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its commercial portfolio includes FILSPARI (sparsentan) for Immunoglobulin A nephropathy (IgAN) and Thiola/Thiola EC for cystinuria. The company is advancing a pipeline including sparsentan for focal segmental glomerulosclerosis (FSGS) and pegtibatinase for classical homocystinuria (HCU).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $490,728 | $233,175 |
| Net Product Sales | $410,460 | $226,707 |
| License & Collaboration Revenue | $80,268 | $6,468 |
| Operating Expenses | $553,552 | $557,002 |
| Net Loss (Continuing Ops) | $(50,261) | $(320,630) |
| Net Loss (Including Discontinued Ops) | $(25,546) | $(321,545) |
| Cash & Cash Equivalents | $93,035 | $58,535 |
| Marketable Debt Securities | $229,761 | $312,166 |
| Total Debt Outstanding | $311,724 | $378,988 |
| Net Working Capital | $277,661 | $215,951 |
Note: The 2025 Net Loss includes a $24.7 million gain from discontinued operations (milestone payment from Mirum Pharmaceuticals).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 110% to $490.7 million, driven by a 144% increase in FILSPARI sales ($322.0 million vs. $132.2 million) and a significant rise in license/collaboration revenue ($80.3 million vs. $6.5 million).
- License Milestones: License revenue surged due to $57.5 million in milestones from CSL Vifor (regulatory and market access) and $9.3 million from the Chugai/Renalys transaction.
- Operating Expenses: Total operating expenses remained relatively flat ($553.6 million vs. $557.0 million). Selling, General, and Administrative (SG&A) expenses increased $73.1 million due to higher intangible asset amortization and commercial investments for FILSPARI. Research and Development (R&D) expenses decreased $11.5 million, partly due to the pause in the pegtibatinase HARMONY study in late 2024.
- Debt Repayment: The company repaid $68.9 million of convertible senior notes due in 2025, reducing total debt.
- Discontinued Operations: Recognized a $25.0 million milestone payment from Mirum Pharmaceuticals related to the 2023 sale of the bile acid product portfolio.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- FILSPARI (IgAN): Received full FDA approval in September 2024. Sales are growing rapidly. The company received a $40.0 million market access milestone from CSL Vifor in Q4 2025.
- FILSPARI (FSGS): Submitted a supplemental New Drug Application (sNDA) in March 2025. The FDA extended the review timeline; the new PDUFA target action date is April 13, 2026.
- Pegtibatinase (HCU): Enrollment in the pivotal Phase 3 HARMONY Study was paused in September 2024 due to manufacturing scale-up issues. Enrollment restarted in Q1 2026 following process optimization.
- Liquidity: Management believes cash and short-term investments ($322.8 million total) are sufficient to fund operations beyond the next 12 months.
Risks and Contingencies
- Regulatory Uncertainty: Approval of sparsentan for FSGS is not guaranteed despite the sNDA submission. The FDA requested additional data to characterize clinical benefit.
- Manufacturing: Reliance on third-party manufacturers poses supply chain risks. The pegtibatinase program faced delays due to manufacturing scale-up challenges.
- Competition: Thiola faces generic competition. The IgAN treatment landscape is evolving with new competitors (e.g., atrasentan, sibeprenlimab).
- Intellectual Property: A third party filed an opposition to a key European patent for sparsentan in 2020; the company is defending it.
- Debt Obligations: The company has $311.7 million in 2029 Convertible Senior Notes outstanding. Failure to generate sufficient cash flow could impact the ability to service debt.
Key Facts for Investor Verification
- FSGS Approval Timeline: Verify the status of the FDA review for the sparsentan FSGS sNDA and the April 13, 2026 PDUFA date.
- Pegtibatinase Enrollment: Confirm the progress of patient enrollment in the HARMONY Study following the Q1 2026 restart.
- FILSPARI Sales Trajectory: Monitor quarterly sales growth of FILSPARI to ensure it meets commercialization expectations following full approval.
- Debt Conversion/Repayment: Track the company's ability to manage the $311.7 million convertible debt maturing in 2029 and potential conversion scenarios.
- Patent Litigation: Monitor the outcome of the opposition to the European Patent No. EP3222277 regarding sparsentan.